CICP1

Across TCGA pan-cancer cohorts, CICP1 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated CICP1 data layer.

The strongest signal is observed in sarcoma (SARC), where higher CICP1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CICP1 expression acts as an unfavorable survival marker.

SARC, PAAD, and READ are the cancer types where CICP1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Tertile	All	0.205	0.747	<.001	45	view →
PAAD	OS	Tertile	II,III,IV	0.205	0.556	.002	36	view →
READ	OS	Tertile	All	0.069	0.917	<.001	36	view →
MESO	DFS	Tertile	All	0.099	0.392	.030	27	view →
THYM	OS	Tertile	All	0.381	0.879	.003	24	view →
CESC	DFS	Tertile	All	0.138	0.740	<.001	18	view →
STAD	DFS	Tertile	IV	0.160	0.402	.044	9	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CICP1–SARC (OS)

Open the SARC breakdown →